{
    "hands_on_practices": [
        {
            "introduction": "Before considering the specifics of an oncologic resection, a surgeon must first assess the patient's overall physiological resilience. This practice focuses on quantifying a patient's baseline health and comorbidities using the Charlson Comorbidity Index ($CCI$), a validated tool for predicting perioperative risk and long-term survival. Mastering this calculation is fundamental to balancing the potential oncologic benefit of metastasectomy against the immediate risks of surgery .",
            "id": "5152963",
            "problem": "An oncologic surgical team is evaluating a patient with limited metastatic colorectal cancer for pulmonary metastasectomy. You are asked to quantify comorbidity burden using the age-adjusted Charlson Comorbidity Index (CCI) and to reason about how the comorbidity burden should alter perioperative risk assessment and candidacy considerations for metastasectomy, grounded in established prognostic scoring definitions and general perioperative risk principles.\n\nUse the following well-tested definitions and scoring rules for the age-adjusted Charlson Comorbidity Index (CCI). Each comorbidity, when present, contributes a specified number of points; if a condition qualifies for a more severe category, do not also score the milder category for the same condition. Age adjustment is additive.\n\nComorbidity categories and points:\n- Myocardial infarction: $1$\n- Congestive heart failure: $1$\n- Peripheral vascular disease: $1$\n- Cerebrovascular disease: $1$\n- Dementia: $1$\n- Chronic pulmonary disease: $1$\n- Connective tissue disease: $1$\n- Peptic ulcer disease: $1$\n- Mild liver disease: $1$\n- Diabetes mellitus without end-organ damage: $1$\n- Hemiplegia: $2$\n- Moderate or severe renal disease: $2$\n- Diabetes mellitus with end-organ damage (for example, retinopathy, nephropathy, neuropathy): $2$\n- Any tumor (solid tumor without metastasis): $2$\n- Leukemia: $2$\n- Lymphoma: $2$\n- Moderate or severe liver disease: $3$\n- Metastatic solid tumor: $6$\n- Acquired Immunodeficiency Syndrome (AIDS): $6$\n\nAge adjustment (age-adjusted CCI):\n- Age $50$ to $59$: add $1$\n- Age $60$ to $69$: add $2$\n- Age $70$ to $79$: add $3$\n- Age $\\geq 80$: add $4$\n\nPatient profile:\n- Age: $68$ years.\n- Primary malignancy: colorectal adenocarcinoma resected $18$ months ago with negative margins; currently 2 fluorodeoxyglucose-avid nodules in a single lung lobe on Positron Emission Tomography (PET) and computed tomography, each approximately $1.2$ cm, no extrathoracic disease on staging; considering pulmonary metastasectomy.\n- Cardiac history: prior myocardial infarction $3$ years ago, percutaneous coronary intervention performed, currently no angina, no heart failure symptoms; left ventricular ejection fraction 45% on recent echocardiography.\n- Pulmonary history: moderate chronic obstructive pulmonary disease on inhaled long-acting bronchodilator and inhaled corticosteroid; baseline Forced Expiratory Volume in 1 second ($FEV_1$) 58% predicted.\n- Endocrine/other: type $2$ diabetes mellitus with documented non-proliferative diabetic retinopathy; no known nephropathy; most recent estimated glomerular filtration rate 62 mL/min per $1.73$ m$^2$.\n- Rheumatologic: rheumatoid arthritis on methotrexate.\n- Gastrointestinal: history of peptic ulcer disease with an upper gastrointestinal bleed $10$ years ago; Helicobacter pylori treated; no recurrent bleeding.\n- No history of cerebrovascular disease, dementia, peripheral vascular disease, liver disease, leukemia, lymphoma, Acquired Immunodeficiency Syndrome (AIDS), or hemiplegia.\n\nTasks:\n1. Based on the definitions above, compute the total age-adjusted Charlson Comorbidity Index (CCI) for this patient. Carefully justify each component you include and avoid double counting where a more severe category supersedes a milder one.\n2. In your reasoning (not in the final numeric answer), explain how the magnitude of the computed comorbidity burden would be expected to influence perioperative risk stratification and candidacy for pulmonary metastasectomy in limited metastatic disease, invoking general, well-accepted perioperative risk principles.\n\nProvide the final numerical result for the age-adjusted CCI as a single integer. No rounding is required beyond exact summation. Do not include any units with your final numeric answer.",
            "solution": "The problem is assessed to be valid. It is scientifically grounded in established medical prognostication tools (the Charlson Comorbidity Index), is well-posed with clearly defined scoring rules and patient data, and is expressed in objective clinical language. A unique numerical solution exists and the qualitative reasoning portion is based on accepted principles of perioperative risk assessment.\n\nThe task is to compute the age-adjusted Charlson Comorbidity Index (CCI) for a given patient and to discuss the implications of this score for surgical decision-making. The calculation will proceed in two stages: first, summing the points for all relevant comorbidities, and second, adding points based on the patient's age.\n\n**Part 1: Calculation of the Age-Adjusted Charlson Comorbidity Index (CCI)**\n\nThe calculation is based on a systematic evaluation of the patient's history against the provided scoring table.\n\n1.  **Oncologic Status**: The patient has colorectal adenocarcinoma with 2 pulmonary nodules, which are characterized as metastatic disease. The scoring system assigns points for \"Metastatic solid tumor\".\n    *   Metastatic solid tumor: 6 points.\n    This category supersedes the \"Any tumor (solid tumor without metastasis)\" category, which would be 2 points, thus preventing double-counting.\n\n2.  **Cardiac History**: The patient has a documented history of a \"prior myocardial infarction\".\n    *   Myocardial infarction: 1 point.\n    The problem notes \"no heart failure symptoms\". Despite a left ventricular ejection fraction of 45%, which may represent asymptomatic cardiac dysfunction, a formal diagnosis of congestive heart failure is not given. Therefore, only the points for myocardial infarction are assigned.\n\n3.  **Pulmonary History**: The patient has a diagnosis of \"moderate chronic obstructive pulmonary disease\".\n    *   Chronic pulmonary disease: 1 point.\n\n4.  **Endocrine History**: The patient has \"type 2 diabetes mellitus with documented non-proliferative diabetic retinopathy\". Retinopathy is a form of end-organ damage.\n    *   Diabetes mellitus with end-organ damage: 2 points.\n    This more severe category supersedes the \"Diabetes mellitus without end-organ damage\" category, which would be 1 point.\n\n5.  **Renal Status**: The patient's most recent estimated glomerular filtration rate is 62 mL/min per 1.73 m$^2$. The category \"Moderate or severe renal disease\" (worth 2 points) is typically defined by an eGFR less than 60 mL/min per 1.73 m$^2$. Since $62 > 60$, the patient does not meet the criteria for this category.\n    *   Moderate or severe renal disease: 0 points.\n\n6.  **Rheumatologic History**: The patient has \"rheumatoid arthritis\".\n    *   Connective tissue disease: 1 point.\n\n7.  **Gastrointestinal History**: The patient has a \"history of peptic ulcer disease\".\n    *   Peptic ulcer disease: 1 point.\n\n8.  **Other Conditions**: The problem explicitly states there is no history of cerebrovascular disease, dementia, peripheral vascular disease, liver disease, hemiplegia, leukemia, lymphoma, or Acquired Immunodeficiency Syndrome (AIDS). These categories contribute 0 points.\n\nThe subtotal of points from comorbidities is the sum of the points from each relevant condition:\n$$\n\\text{Comorbidity score} = \\underbrace{6}_{\\text{Metastatic tumor}} + \\underbrace{1}_{\\text{MI}} + \\underbrace{1}_{\\text{COPD}} + \\underbrace{2}_{\\text{Diabetes w/ EOD}} + \\underbrace{1}_{\\text{CTD}} + \\underbrace{1}_{\\text{PUD}} = 12\n$$\n\nNext, the age adjustment is applied. The patient is 68 years old. According to the rules, the age range 60 to 69 corresponds to an additional point allocation.\n*   Age adjustment for 68 years: 2 points.\n\nThe total age-adjusted Charlson Comorbidity Index is the sum of the comorbidity score and the age adjustment points.\n$$\n\\text{Age-adjusted CCI} = \\text{Comorbidity score} + \\text{Age adjustment} = 12 + 2 = 14\n$$\n\n**Part 2: Reasoning on Perioperative Risk and Candidacy**\n\nThe computed age-adjusted CCI is 14. This is a very high score, indicating a substantial burden of comorbid disease and a correspondingly high risk of mortality. The CCI was originally developed to predict 1-year mortality, and a higher score correlates strongly with increased perioperative morbidity and mortality as well as reduced long-term overall survival, independent of the cancer diagnosis itself. The magnitude of this score must be a central element in the perioperative risk assessment and discussions of surgical candidacy for pulmonary metastasectomy.\n\nThe influence of this comorbidity burden can be analyzed through its components:\n\n1.  **Oncologic Burden**: The largest single contributor to the score is the metastatic cancer itself (6 points). This highlights the fundamental reality that the patient's long-term prognosis is primarily dictated by the biology and trajectory of their colorectal cancer. The goal of metastasectomy in this setting is to achieve a \"no evidence of disease\" status with the aim of prolonged survival or even cure. However, this is only achievable if the patient can survive the surgery and recover adequately.\n\n2.  **Cardiopulmonary Limitation**: The patient has significant, established cardiorespiratory disease. The prior myocardial infarction (1 point) and moderate COPD (1 point) represent major risk factors for a major thoracic operation. Pulmonary resection imposes acute physiologic stress: it reduces lung volume, can lead to ventilation-perfusion mismatch, and requires single-lung ventilation during surgery, all of which are poorly tolerated in patients with pre-existing COPD. The $FEV_1$ of 58% predicted indicates limited pulmonary reserve. Similarly, the history of MI, even with revascularization, and a mildly reduced ejection fraction (45%) place the patient at elevated risk for perioperative cardiac events such as arrhythmias, heart failure exacerbation, or myocardial ischemia.\n\n3.  **Systemic Disease**: Diabetes with end-organ damage (2 points) and rheumatoid arthritis (1 point) reflect systemic conditions that impair physiological resilience. They are associated with micro- and macrovascular disease, compromised immune function (from the disease or its treatment, e.g., methotrexate for RA), and impaired wound healing, all of which increase the risk of postoperative complications like surgical site infections, pneumonia, and sepsis.\n\n**Synthesis and Candidacy Implications**:\nA cumulative CCI of 14 places the patient in a very high-risk stratum. The decision to proceed with pulmonary metastasectomy requires a rigorous and sober assessment of risk versus benefit. The high CCI score predicts that the patient's risk of dying from their comorbidities in the short-to-medium term may rival or exceed their risk of dying from their \"limited\" metastatic cancer.\n\nFor candidacy, this score mandates several actions:\n-   **Extensive Preoperative Evaluation**: A comprehensive workup including formal pulmonary function tests with diffusing capacity (DLCO), cardiac stress testing, and a detailed cardiology and pulmonology consultation is not merely advisable but obligatory.\n-   **Formal Risk Stratification**: Quantitative risk calculators (e.g., ACS-NSQIP surgical risk calculator) should be used to provide the patient and the surgical team with objective estimates of mortality, major complications, and length of stay. The patient's high CCI score will drive these risk estimates upwards significantly.\n-   **Discussion of Alternatives**: The high operative risk makes non-operative or less invasive treatments more attractive. Alternatives such as stereotactic body radiation therapy (SBRT), which can achieve excellent local control of lung nodules with much less physiologic trespass, must be seriously considered and discussed as a primary option. Continuing or modifying systemic therapy without local treatment is also an option.\n-   **Shared Decision-Making**: The conversation with the patient must explicitly weigh the potential for long-term survival from successful surgery against the substantial immediate risk of life-threatening complications or death. The high CCI score reframes the question from \"Can we technically resect the metastases?\" to \"Should we subject this physiologically fragile patient to a major operation, and is it consistent with their goals of care?\" In many multidisciplinary tumor board discussions, a patient with this degree of comorbidity would be considered a marginal or poor candidate for major thoracic surgery.",
            "answer": "$$\n\\boxed{14}\n$$"
        },
        {
            "introduction": "A successful metastasectomy depends on the accurate identification of patients with truly localized metastatic disease. This exercise simulates the process of using advanced imaging, like Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography (FDG PET-CT), to refine staging and avoid futile surgery. By applying principles of Bayesian probability, you will learn to calculate the diagnostic yield and predictive value of a test, transforming raw sensitivity and specificity data into clinically meaningful probabilities that guide patient selection .",
            "id": "5152912",
            "problem": "A tertiary hepatobiliary surgical unit evaluates candidates for salvage hepatic metastasectomy in colorectal cancer patients with limited hepatic disease on standard staging using contrast-enhanced computed tomography (CT). Despite liver-limited findings on CT, a proportion of these patients harbor occult extrahepatic disease that would preclude curative metastasectomy. The unit considers adding Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography (FDG PET-CT) to refine selection.\n\nAssume the following, all referring to the cohort deemed liver-limited by CT:\n- The pretest probability of occult extrahepatic disease is $P(\\text{disease}) = 0.20$.\n- FDG PET-CT sensitivity for extrahepatic disease is $P(\\text{PET+}|\\text{disease}) = 0.85$.\n- FDG PET-CT specificity for absence of extrahepatic disease is $P(\\text{PET-}|\\neg\\text{disease}) = 0.92$.\n\nFor this cohort, define the incremental staging yield of FDG PET-CT for extrahepatic disease as the proportion of patients who will be correctly upstaged by FDG PET-CT due to detection of extrahepatic disease not identified on CT. Using the fundamental definitions of sensitivity, specificity, and Bayes’ theorem, first derive a symbolic expression for this incremental staging yield and evaluate it numerically from the given parameters. Then, compute the post-test probability of occult extrahepatic disease given a positive FDG PET-CT, using\n$$\nP(\\text{disease}|\\text{PET+}) = \\frac{P(\\text{PET+}|\\text{disease})\\,P(\\text{disease})}{P(\\text{PET+})},\n$$\nwith\n$$\nP(\\text{PET+}) = P(\\text{PET+}|\\text{disease})\\,P(\\text{disease}) + P(\\text{PET+}|\\neg\\text{disease})\\,P(\\neg\\text{disease}).\n$$\nReport the final answer as the post-test probability $P(\\text{disease}|\\text{PET+})$ expressed as a decimal proportion. Round your final answer to four significant figures.",
            "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in the principles of Bayesian probability theory as applied to medical diagnostics, a standard and well-established methodology. The problem is well-posed, providing all necessary parameters and definitions for a unique solution. The language is objective and the data are consistent.\n\nThe problem requires the calculation of two quantities related to the diagnostic performance of FDG PET-CT for detecting occult extrahepatic disease in a specific patient cohort. The given parameters are:\n- The pretest probability (prevalence) of occult extrahepatic disease: $P(\\text{disease}) = 0.20$.\n- The sensitivity of the test: $P(\\text{PET+}|\\text{disease}) = 0.85$.\n- The specificity of the test: $P(\\text{PET-}|\\neg\\text{disease}) = 0.92$.\n\nFirst, we will address the incremental staging yield. This is defined as the proportion of all patients in the cohort who are correctly upstaged, meaning they have the disease and the test correctly identifies it. This corresponds to the joint probability of having the disease and testing positive, $P(\\text{disease} \\cap \\text{PET+})$. Using the definition of conditional probability, this is given by:\n$$\n\\text{Yield} = P(\\text{disease} \\cap \\text{PET+}) = P(\\text{PET+}|\\text{disease}) \\times P(\\text{disease})\n$$\nSubstituting the given values:\n$$\n\\text{Yield} = 0.85 \\times 0.20 = 0.17\n$$\nThis means that $17\\%$ of the entire cohort will be correctly identified by FDG PET-CT as having occult extrahepatic disease.\n\nSecond, we must compute the post-test probability of disease given a positive test result, $P(\\text{disease}|\\text{PET+})$. The problem explicitly provides Bayes' theorem for this calculation:\n$$\nP(\\text{disease}|\\text{PET+}) = \\frac{P(\\text{PET+}|\\text{disease})\\,P(\\text{disease})}{P(\\text{PET+})}\n$$\nThe numerator is the incremental staging yield we just calculated: $P(\\text{PET+}|\\text{disease})P(\\text{disease}) = 0.17$.\n\nThe denominator, $P(\\text{PET+})$, is the overall probability of a positive test result in this cohort. It is found using the law of total probability, as provided:\n$$\nP(\\text{PET+}) = P(\\text{PET+}|\\text{disease})P(\\text{disease}) + P(\\text{PET+}|\\neg\\text{disease})P(\\neg\\text{disease})\n$$\nTo evaluate this expression, we need the probabilities $P(\\neg\\text{disease})$ and $P(\\text{PET+}|\\neg\\text{disease})$.\nThe probability of not having the disease is the complement of having the disease:\n$$\nP(\\neg\\text{disease}) = 1 - P(\\text{disease}) = 1 - 0.20 = 0.80\n$$\nThe probability $P(\\text{PET+}|\\neg\\text{disease})$ is the false positive rate. It is the complement of the specificity, $P(\\text{PET-}|\\neg\\text{disease})$:\n$$\nP(\\text{PET+}|\\neg\\text{disease}) = 1 - P(\\text{PET-}|\\neg\\text{disease}) = 1 - 0.92 = 0.08\n$$\nNow we can calculate the denominator, $P(\\text{PET+})$:\n$$\nP(\\text{PET+}) = (0.85 \\times 0.20) + (0.08 \\times 0.80)\n$$\n$$\nP(\\text{PET+}) = 0.17 + 0.064 = 0.234\n$$\nThis is the total probability of a positive test, comprising both true positives ($0.17$) and false positives ($0.064$).\n\nFinally, we substitute the numerator and denominator into Bayes' theorem to find the post-test probability:\n$$\nP(\\text{disease}|\\text{PET+}) = \\frac{0.17}{0.234} \\approx 0.7264957...\n$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$\nP(\\text{disease}|\\text{PET+}) \\approx 0.7265\n$$\nThis is the positive predictive value of the test in this specific patient population.",
            "answer": "$$\n\\boxed{0.7265}\n$$"
        },
        {
            "introduction": "The goal of metastasectomy is not just to remove all visible disease, but to do so while preserving adequate organ function for a good quality of life. This practice focuses on a key aspect of surgical planning: predicting the postoperative physiological reserve after lung resection. You will use the anatomical segment-counting method to estimate the remaining lung function, a critical calculation that directly informs the feasibility and safety of the proposed operation .",
            "id": "5152982",
            "problem": "A patient with oligometastatic colorectal adenocarcinoma limited to the lung has completed systemic therapy and is scheduled for salvage pulmonary metastasectomy comprising resection of left segment $6$ and a lingulectomy (segments $4$ and $5$), for a total of $s = 3$ anatomical segments. Preoperative spirometry and gas transfer testing show a forced expiratory volume in one second ($FEV_1$) of $2.80$ liters, which corresponds to $0.85$ of predicted normal for this patient, and a diffusing capacity for carbon monoxide ($DLCO$) of $0.68$ as a decimal fraction of predicted. Assume the standard anatomical model of $19$ lung segments, homogeneous baseline distribution of ventilation and perfusion across segments, and that each resected segment removes a proportional share of global function.\n\nUsing only these assumptions, derive the predicted postoperative values for $FEV_1$ and $DLCO$ based on the fraction of lung parenchyma preserved after resection. Then compute the numerical values for the predicted postoperative $FEV_1$ and predicted postoperative $DLCO$ for this patient. Round both numerical results to four significant figures. Express the predicted postoperative $FEV_1$ in liters and the predicted postoperative $DLCO$ as a decimal fraction of predicted (do not use a percent sign). Finally, in your reasoning, interpret whether these predicted postoperative values meet commonly accepted safety thresholds for multi-segment pulmonary resection in the context of salvage metastasectomy.",
            "solution": "The problem is well-posed, scientifically grounded, and provides sufficient information for a unique solution. The scenario is a standard clinical problem in thoracic surgical oncology concerning the preoperative assessment of physiological risk. The assumptions, while a simplification of complex pulmonary physiology, are explicitly stated and form the basis of a common and accepted method for estimating postoperative lung function. Therefore, the problem is valid, and we may proceed with the solution.\n\nThe primary task is to calculate the predicted postoperative forced expiratory volume in one second ($\\mathrm{ppoFEV}_1$) and the predicted postoperative diffusing capacity for carbon monoxide ($\\mathrm{ppoDLCO}$) using the anatomical segment counting method.\n\nLet $N$ be the total number of bronchopulmonary segments in the standard anatomical model. The problem states this value is $N=19$. This model consists of $10$ segments in the right lung and $9$ segments in the left lung (segments $1$ and $2$ are fused in the apicoposterior segment of the left upper lobe).\n\nLet $s$ be the number of segments to be resected. The planned surgery involves resection of left segment $6$ (the superior segment of the left lower lobe) and a lingulectomy, which comprises segments $4$ (superior lingular) and $5$ (inferior lingular). Thus, the total number of resected segments is $s = 1 + 2 = 3$.\n\nThe fundamental assumption is that pulmonary function (both ventilation, measured by $FEV_1$, and gas exchange, measured by $DLCO$) is homogeneously distributed across all $N$ segments. Consequently, the loss of function is directly proportional to the fraction of lung parenchyma resected.\n\nThe fraction of lung parenchyma preserved after resection, denoted by $f_{\\text{preserved}}$, is the ratio of the number of remaining segments to the total number of segments:\n$$f_{\\text{preserved}} = \\frac{N-s}{N}$$\nSubstituting the given values, we find:\n$$f_{\\text{preserved}} = \\frac{19 - 3}{19} = \\frac{16}{19}$$\nThe predicted postoperative value of any functional parameter, which we can denote generically as $F_{\\text{ppo}}$, is calculated by multiplying its preoperative value, $F_{\\text{pre}}$, by the fraction of preserved lung tissue:\n$$F_{\\text{ppo}} = F_{\\text{pre}} \\times f_{\\text{preserved}} = F_{\\text{pre}} \\times \\frac{N-s}{N}$$\nWe apply this general formula to both $FEV_1$ and $DLCO$.\n\nFirst, we calculate the predicted postoperative $FEV_1$ ($\\mathrm{ppoFEV}_1$) in liters. The preoperative value is given as $\\mathrm{FEV}_{1,\\text{pre}} = 2.80$ liters.\n$$\\mathrm{ppoFEV}_1 = \\mathrm{FEV}_{1,\\text{pre}} \\times \\frac{16}{19}$$\n$$\\mathrm{ppoFEV}_1 = 2.80 \\times \\frac{16}{19} = \\frac{44.8}{19} \\approx 2.3578947... \\text{ liters}$$\nRounding this result to four significant figures gives:\n$$\\mathrm{ppoFEV}_1 \\approx 2.358 \\text{ liters}$$\nSecond, we calculate the predicted postoperative $DLCO$ ($\\mathrm{ppoDLCO}$) as a decimal fraction of the predicted normal value. The preoperative value is given as $\\mathrm{DLCO}_{\\text{pre}} = 0.68$.\n$$\\mathrm{ppoDLCO} = \\mathrm{DLCO}_{\\text{pre}} \\times \\frac{16}{19}$$\n$$\\mathrm{ppoDLCO} = 0.68 \\times \\frac{16}{19} = \\frac{10.88}{19} \\approx 0.5726315...$$\nRounding this result to four significant figures gives:\n$$\\mathrm{ppoDLCO} \\approx 0.5726$$\nThe problem also requires an interpretation of whether these predicted postoperative values meet commonly accepted safety thresholds. To do this, we must express both $\\mathrm{ppoFEV}_1$ and $\\mathrm{ppoDLCO}$ as a fraction or percentage of their predicted normal values.\n\nFor $DLCO$, the calculated value $\\mathrm{ppoDLCO} \\approx 0.5726$ is already in the required format, representing $57.26\\%$ of the predicted normal $DLCO$.\n\nFor $FEV_1$, the preoperative value of $2.80$ liters corresponds to $0.85$ of the predicted normal value. The predicted postoperative value, as a fraction of predicted normal, can be calculated by applying the same reduction factor to this preoperative fraction:\n$$\\mathrm{ppoFEV}_{1,\\%\\text{pred}} = (\\mathrm{FEV}_{1,\\text{pre}} \\text{ as fraction of predicted}) \\times f_{\\text{preserved}}$$\n$$\\mathrm{ppoFEV}_{1,\\%\\text{pred}} = 0.85 \\times \\frac{16}{19} = \\frac{13.6}{19} \\approx 0.715789...$$\nThis corresponds to approximately $71.58\\%$ of the predicted normal $FEV_1$.\n\nStandard clinical guidelines, such as those from the American College of Chest Physicians (ACCP) and the European Society of Thoracic Surgeons (ESTS), generally consider a patient to be at acceptable risk for major lung resection if both the predicted postoperative $FEV_1$ and $DLCO$ are greater than $40\\%$ of their predicted normal values. Some sources may use a more conservative threshold of $30\\%$, below which further, more complex physiological testing (e.g., exercise testing with VO2 max measurement) is warranted.\n\nIn this case, the calculated values are:\n$$\\mathrm{ppoFEV}_{1,\\%\\text{pred}} \\approx 71.6\\%$$\n$$\\mathrm{ppoDLCO}_{\\%\\text{pred}} \\approx 57.3\\%$$\nBoth of these values are well above the conventional safety threshold of $40\\%$. Therefore, based on this anatomical prediction model, the patient is predicted to have sufficient pulmonary reserve to tolerate the planned three-segment metastasectomy, and the procedure falls within acceptable limits of operative risk from a physiological standpoint.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n2.358 & 0.5726\n\\end{pmatrix}\n}\n$$"
        }
    ]
}